The global Immune Checkpoint Inhibitors market was valued at US$ 12550 million in 2020 and is expected to reach US$ 36030 million by the end of 2027, growing at a CAGR of 16.1% during 2021-2027.
Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
Global Immune Checkpoint Inhibitors Market: Drivers and Restrains
The research report has incorporated the analysis of different factors that augment the market’s growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and about each type from 2016 to 2027. This section mentions the volume of production by region from 2016 to 2027. Pricing analysis is included in the report according to each type from the year 2016 to 2027, manufacturer from 2016 to 2021, region from 2016 to 2021, and global price from 2016 to 2027.
A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert’s opinions have been taken to understand the market better.
Global Immune Checkpoint Inhibitors Market: Segment Analysis
The research report includes specific segments by region (country), by manufacturers, by Type and by Application. Each type provides information about the production during the forecast period of 2016 to 2027.
Key Companies profiled in this report are Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences and more in terms of market share by sales, revenue, average pricing, product type, margins, recent developments etc.
Segment by Type
Segment by Application
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Blood Cancer
Table of Content:
1 Immune Checkpoint Inhibitors Market Overview
2 Immune Checkpoint Inhibitors Market Competition by Manufacturers
3 Immune Checkpoint Inhibitors Retrospective Market Scenario by Region
4 Global Immune Checkpoint Inhibitors Historic Market Analysis by Type
5 Global Immune Checkpoint Inhibitors Historic Market Analysis by Application
6 Key Companies Profiled
7 Immune Checkpoint Inhibitors Manufacturing Cost Analysis
8 Marketing Channel, Distributors and Customers
9 Immune Checkpoint Inhibitors Market Dynamics
10 Global Immune Checkpoint Inhibitors Market Forecast
11 Research Finding and Conclusion
12 Methodology and Data Source
Company Name: The Market Reports
Contact Person: Shirish Gupta
Peter Barzilai is a high school pitcher and college rower turned longtime World News journalist. Peter has also written for Buzz Feed and Huffington Post and many other major publications, Peter Loves everything about sports and loves to write on trending topics and he is DailyFactsNTrends member since 2017.